In a major drive to raise awareness about signs, symptoms and risk factors for pancreatic cancer, over 70 Boston-area primary care clinicians attended Immunovia´s educational symposium at Fenway Park, on World Pancreatic Cancer Day 2018
On November 15, 2018, Immunovia, Inc. sponsored an educational symposium at Fenway Park in honor of World Pancreatic Cancer Day, a day when people across the globe work together to increase awareness of the signs and symptoms of pancreatic cancer. Immunovia’s goal for the day was to increase awareness of the signs, symptoms and risk factors for pancreatic cancer among primary care clinicians in the Boston area, and to inform about Immunovia´s test for early diagnosis of pancreatic cancer.
Wearing the familiar purple, over 70 clinicians gathered at the Royal Rooters Club at Fenway Park. The majority of attendees were primary care clinicians; other people in attendance were people who have been personally affected by pancreatic adenocarcinoma. Brigitte Régnier, Board Member of the Alliance of Families Fighting Pancreatic Cancer, started the evening by sharing the important role her primary care physician played in diagnosing her pancreatic cancer early and referring her immediately to specialty care at a medical center with expertise in pancreatic cancer. She was followed by Dr. James Farrell, Director of the Yale Center for Pancreatic Diseases at Yale New Haven Hospital and Professor of Medicine at Yale School of Medicine, and Dr. A. James Moser, Co-Director of the Pancreas & Liver Institute at the Beth Israel Deaconess Medical Center and Associate Professor of Surgery at Harvard Medical School.
Presentations featured case studies, highlighting which patients are at greatest risk for developing pancreatic cancer, and the non-specific early signs and symptoms associated with pancreatic cancer with a particular focus on the link between late onset diabetes and pancreatic cancer. Presenters emphasized the role primary care clinicians can play in detecting pancreatic cancer early and improving outcomes. Dr. Moser also presented some of the new research in treating pancreatic cancer, including the role of minimally invasive surgery and the use of organoids to determine which treatments will be most effective in a specific patient. As Dr. Moser said, “I can’t think of a better place than Fenway Park to stage a comeback in pancreatic cancer.”
Following the program, attendees expressed their appreciation to the event organizers, with one primary care clinician attendee saying: “Thanks so much for hosting an amazing event on this important topic. We learned a lot that will directly benefit our patients.”
Mats Grahn, CEO, Immunovia concluded: “Based on feedback already received, we can say we have achieved our primary goal for this years´ World Pancreatic Cancer Day, which was to increase awareness of the signs, symptoms and risk factors for pancreatic cancer among primary care clinicians in the Boston area, as well as inform about the value of early diagnosis. Immunovia is planning to run such educational programs about recognizing early signs and symptoms of pancreatic cancer already in primary care, in both Europe and USA, as part of the launch of our early detection strategy for pancreatic cancer.”
The program was streamed on Facebook Live (www.facebook.com/ImmunoviaAB/) and can be viewed on Immunovia´s webpage: www.immunovia.com, on-demand on both Facebook and at www.worldpancreaticcancerday.se.